Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.59 |
| ▸ | CA1 | P00915 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926118 | 0.86 | CA12 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL11294063 | 0.85 | CA12 (0.62) | CA12CA1CA2CA9LMNA | |
| SCHEMBL18295353 | 0.84 | CA1 (0.64) | CA12CA1CA2CA9LMNA | |
| SCHEMBL17974334 | 0.83 | CA12 (0.66) | CA12CA1CA2CA9LMNA | |
| SCHEMBL17974332 | 0.83 | CA12 (0.66) | CA12CA1CA2CA9LMNA | |
| SCHEMBL14811632 | 0.82 | CA12 (0.64) | CA12CA1CA2CA9LMNA | |
| SCHEMBL17987635 | 0.82 | CA12 (0.64) | CA12CA1CA2CA9LMNA | |
| SCHEMBL18226889 | 0.82 | CA12 (0.68) | CA12CA1CA2CA9LMNA | |
| SCHEMBL3683825 | 0.82 | CA12 (0.64) | CA12CA1CA2CA9LMNA | |
| SCHEMBL14812141 | 0.81 | CA1 (0.62) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
| EP-1742918-A1 | LXR RECEPTOR MODULATORS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005121093-A1 | LXR RECEPTOR MODULATORS | LABORATOIRES FOURNIER S.A. (FR) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | CA12 4858/4885CA1 4801/4885CA2 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.